This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Sygnis Bioscience Gmbh & Co Kg. Active years: 2008.
Company Filing History:
Years Active: 2008
Title: The Innovations of Markus Schwaninger
Introduction
Markus Schwaninger is a notable inventor based in Heidelberg, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic approaches for neurological conditions. His work has implications for the treatment of apoplexy, showcasing the intersection of genetics and medicine.
Latest Patents
One of Schwaninger's key patents is titled "Nucleic acid molecule encoding a neuronal serine-threonine protein kinase." This invention relates to a gene and the protein it encodes, which plays a crucial role in the development of sequelae of local ischaemia. The new protein is identified as a serine-threonine protein kinase, offering a novel therapeutic approach to both the prophylaxis and therapy of apoplexy. This patent highlights his innovative contributions to medical science, with a focus on improving patient outcomes.
Career Highlights
Throughout his career, Markus Schwaninger has worked with prominent companies in the biotechnology sector. He has been associated with Sygnis Bioscience GmbH & Co. KG and Biogen Idec, Inc. These experiences have allowed him to collaborate with leading experts and contribute to groundbreaking research in his field.
Collaborations
Some of his notable coworkers include Bernhard Götz and Dieter Newrzella. Their collaborative efforts have further advanced the research and development of innovative solutions in biotechnology.
Conclusion
Markus Schwaninger's work exemplifies the vital role of inventors in advancing medical science. His patent on a neuronal serine-threonine protein kinase represents a significant step forward in the treatment of neurological conditions. Through his career and collaborations, he continues to impact the field positively.